p21waf negative | p21waf positive | Total | |||||
---|---|---|---|---|---|---|---|
n | % | n | % | n | % | p Value | |
Univariate statistical calculation using χ2 test. | |||||||
Receptor status: positive, ER positive and/or PR positive; negative, ER negative and PR negative; detection by immunohistochemistry. | |||||||
Steroid hormone receptor status was determined in 132 women, PCNA in 131, Her2/neu expression in 130, and p53 expression in 131 samples. | |||||||
ER, oestrogen receptor; NS, not significant; PCNA, proliferating cell nuclear antigen; PR, progesterone receptor. | |||||||
Age (years) | |||||||
< 50 years | 34 | 25.4 | 13 | 9.7 | 47 | 35.1 | |
> 50 | 56 | 41.8 | 31 | 23.1 | 87 | 64.9 | NS |
Menopausal status | |||||||
Pre | 25 | 18.7 | 10 | 7.5 | 35 | 26.1 | |
Peri | 14 | 10.4 | 7 | 5.2 | 21 | 15.7 | |
Post | 51 | 38.1 | 27 | 20.1 | 78 | 58.2 | NS |
Tumour size (cm) | |||||||
< 2 | 48 | 35.8 | 17 | 12.7 | 65 | 48.5 | |
2–5 | 41 | 30.6 | 19 | 14.2 | 60 | 44.8 | |
> 5 | 1 | 0.7 | 8 | 6.0 | 9 | 6.7 | 0.001 |
Tumour grade | |||||||
GI | 15 | 11.2 | 10 | 7.5 | 25 | 18.7 | |
GII | 53 | 39.6 | 21 | 15.7 | 74 | 55.2 | |
GIII | 22 | 16.4 | 13 | 9.7 | 35 | 26.1 | NS |
Receptor status | |||||||
Negative | 25 | 18.9 | 13 | 9.8 | 38 | 28.8 | |
Positive | 63 | 47.7 | 31 | 23.5 | 94 | 71.2 | NS |
PCNA | |||||||
< 10% | 45 | 34.4 | 20 | 15.3 | 65 | 49.6 | |
10–49% | 33 | 25.2 | 11 | 8.4 | 44 | 33.6 | |
> 50% | 9 | 6.9 | 13 | 9.9 | 22 | 16.8 | 0.017 |
Her2/neu | |||||||
Negative | 67 | 51.5 | 37 | 28.5 | 104 | 80.0 | |
Positive | 20 | 15.4 | 6 | 4.6 | 26 | 20.0 | NS |
p53 | |||||||
Negative | 59 | 45.0 | 26 | 19.8 | 85 | 64.9 | |
Positive | 30 | 22.9 | 16 | 12.2 | 46 | 35.1 | NS |
p21waf | 90 | 67.2 | 44 | 32.8 |